(redirected from Dalvance)


(dal-ba-van-sin ),


(trade name)


Therapeutic: anti infectives
Pharmacologic: lipoglycopeptides
Pregnancy Category: C


Treatment of skin/skin structure infections due to susceptible bacteria.


Binds to bacterial cell wall resulting in cell death.

Therapeutic effects

Bactericidal action against susceptible bacteria with resolution of infection.
Active against Staphylococcus aureus (including methicillin-susceptible and resistant strains), Streptococcus agalactiae, Streptococcus anginosus (including S. anginosus, S. intermidius and S. constellatus) and Streptococcus pyogenes.


Absorption: IV administration results in complete bioavailability.
Distribution: Penetrates tissues and fluids.
Metabolism and Excretion: 33% eliminated unchanged in urine, 12% eliminated as inactive metabolite, 20% excreted in feces.
Half-life: 346 hr.

Time/action profile (blood levels)

IVunknownend of infusion1 wk


Contraindicated in: Hypersensitivity.
Use Cautiously in: Renal impairment (dose adjustment required for CCr <30 mL/min; Moderate to severe hepatic impairment; Geriatric: Consider age-related decrease in renal function; Obstetric: Use during pregnancy only if potential benefit justifies potential risk to the fetus; Lactation: Use cautiously if breastfeeding; Pediatric: Safe and effective use in children has not been established.

Adverse Reactions/Side Effects

Central nervous system

  • headache


  • diarrhea including Clostridium difficile (life-threatening)
  • nausea
  • ↑ ALT


  • pruritus
  • rash


  • hypersensitivity reactions including anaphylaxis (life-threatening)
  • infusion reactions including “Red-Man Syndrome”


Drug-Drug interaction

None noted.


Intravenous (Adults) 1000 mg followed one wk later by 500 mg.

Renal Impairment

Intravenous (Adults) CCr <30 mL/min—750 mg followed one wk later by 375 mg.


Lyophylized powder for intravenous injection (requires reconstitution and further dilution): 500 mg single-use vial

Nursing implications

Nursing assessment

  • Assess for infection (vital signs; appearance of wound, sputum, urine, and stool; WBC) at beginning of and during therapy.
  • Obtain specimens for culture and sensitivity prior to therapy. First dose may be given before receiving results.
  • Monitor bowel function. Diarrhea, abdominal cramping, fever, and bloody stools should be reported to health care professional promptly as a sign of pseudomembranous colitis. May begin up to 2 mo following cessation of therapy.
  • Monitor for infusion reactions (Red-man syndrome — flushing of upper body, urticaria, pruritus, rash). May resolve with stopping or slowing infusion.
  • Lab Test Considerations: Monitor hepatic function tests. May cause ↑ ALT, AST, and bilirubin.

Potential Nursing Diagnoses

Risk for infection (Indications)
Diarrhea (Adverse Reactions)


  • Intravenous Administration
  • Intermittent Infusion: Reconstitute with 25 mL of Sterile water in each 500 mg vial. Alternate gentle swirling and inverting to avoid foaming, until completely dissolved. Do not shake. Reconstituted vial contains a clear colorless to yellow solution. Do not administer solutions that are discolored or contain particulate matter. Transfer reconstituted solution into D5W. Concentration: 1 mg/mL to 5 mg/mL. Discard unused solution. May be refrigerated or kept at room temperature; do not freeze. Infuse within 48 hr of reconstitution. Do not administer solutions containing particulate matter.
  • Rate: Infuse over 30 min.
  • Y-Site Incompatibility: Do not infuse with other medications or electrolytes. Saline solutions may cause precipitation. Flush line before and after infusion with D5W.

Patient/Family Teaching

  • Instruct patient to notify health care professional if signs and symptoms of hypersensitivity reactions (rash, hives, dyspnea, facial swelling) occur.
  • Instruct patient to notify health care professional immediately if diarrhea, abdominal cramping, fever, or bloody stools occur and not to treat with antidiarrheals without consulting health care professionals
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patients to use effective contraception during therapy and to notify health care professional if pregnancy is suspected or if breastfeeding.
  • Instruct the patient to notify health care professional if symptoms do not improve.

Evaluation/Desired Outcomes

  • Resolution of the signs and symptoms of infection. Length of time for complete resolution depends on the organism and site of infection.
References in periodicals archive ?
Dalbavancin is commercialised under the trade name Dalvance in the US and Xydalba in certain countries outside the US Cardiome has rights to commercialise Xydalba under an agreement with Allergan plc in France, the United Kingdom, Germany, Belgium, Nordic countries, certain other Western European countries, various Middle Eastern countries, and Canada.
Browse Hospital-Acquired Infection Therapeutics Market by Drug Type (Antibacterial, Antifungal and Antiviral Drugs), Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs (Amikacin Inhale, CAZ AVI Ceftolozane, Dalvance, Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin, Tedizolid), and Indications (Blood Stream Infections, Gastrointestinal Disorders, HAP, SSIs, UTIs) 2016-2020 report at https://www.
Additional data will highlight AVYCAZ (ceftazidime and avibactam) clinical efficacy and susceptibility in certain difficult-to-treat pathogens; DALVANCE (dalbavancin) pediatric safety and in vitro activity in Gram-positive pathogens causing ABSSSI; and TEFLARO (ceftaroline fosamil) clinical outcomes and in vitro activity in Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
DALVANCE (dalbavancin) is marketed in the United States by Allergan plc.
For what such numbers are worth, market analysts predict sales of $204 million for Dalvance, of $309 million for Orbactiv, and of $216 million for Sivextro by 2020.
00 per share if certain regulatory or commercial milestones regarding Durata's flagship product, Dalvance, are met.
Approval of Sivextro, known also as tedizolid, comes in the aftermath of regulatory clearance of the drug Dalvance for the same condition and manufactured by Durata Therapeutics Inc.
Her expertise ranges across various infectious disease products, including Avycaz, Dalvance, Teflaro, Levaquin and Floxin.
The agency approved Dalvance (dalbavancin) in May, Sivextro (tedizolid) in June and Orbactiv (oritavancin) in August.
M2 EQUITYBITES-October 12, 2015-Allergan's DALVANCE sNDA accepted by the US FDA for filing
On October 6, 2014, WilmerHale client Durata Therapeutics announced that it had entered into a definitive merger agreement with Actavis plc under which a subsidiary of Actavis will commence a tender offer to acquire all of the outstanding shares of Durata common stock for $23 per share in cash, or approximately $675 million in the aggregate, and contingent value rights entitling the holder to receive additional cash payments of up to $5 per share if certain regulatory or commercial milestones related to Durata's lead product DALVANCE are achieved.
M2 PHARMA-October 12, 2015-Allergan's DALVANCE sNDA accepted by the US FDA for filing